De-Risking Strategies For Schizophrenia Programs

Schizophrenia drug development is approaching a critical breaking point, with rising placebo response rates undermining signal detection and putting promising therapies at risk. In this webinar, leading experts Dr. Jeffrey Lieberman, Dr. Alan Kott, and Dr. Chris Murphy dissect why Phase 3 failures are increasing, how data quality issues cluster at specific sites, and why inadequate dose-response mapping continues to derail programs. They explore emerging acuity markers — such as baseline anxiety — that may help distinguish true acute exacerbations, examine how external events can distort trial outcomes, and outline practical strategies to predict risk, restrict inappropriate subjects, and intervene early to protect trial integrity. Whether you're preparing for Phase 3 or looking to safeguard a promising mechanism, this session offers a grounded, data-driven look at the operational and scientific factors that determine success in today’s high-risk schizophrenia trials.